Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2185 participants.

Also called NCT01351675

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,185 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01351675
Other papers using this trial's data
  • Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease The New England journal of medicine, 2013-12-26 DOI, PubMed 24206459, PMC4496027 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01351675. Randomized; quadruple masking; primary purpose treatment. Start 2011-06-30 (actual); primary completion 2012-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Acronym
BEACON
Condition
Renal Insufficiency, Chronic
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Bardoxolone Methyl: 20 mg
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct01351675
Content hash
75b38e8e7ed0acae8efede32716cfcaa6d9d68119a30c86f13610926a8108594